3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
39
Neoplasms
16
Neoplasm Metastasis
8
Colorectal Neoplasms
5
Thyroid Neoplasms
3
Skin Neoplasms
2
Recurrence
2
Leukemia, Hairy Cell
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Cancer, Papillary
1
Skin Diseases
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Noonan syndrome 3
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Histiocytosis, Langerhans-Cell
1
Heterotaxy Syndrome
1
Hepatoblastoma
1
Glioma
1
Interventions
binimetinib
2
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Trabectedin
1
Spironolactone
1
Paclitaxel
1
Low-Level Light Therapy
1
Leuprolide
1
Fluorouracil
1
Everolimus
1
Equipment and Supplies
1
Dacarbazine
1
Cetuximab
1
Cantharidin
1
BF-200 ALA
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Skin Diseases
×
Vemurafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA